| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5387603 | ALLERGAN | 1,5,7-trisubstituted indoline compounds and salts thereof |
Dec, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5403847 | ALLERGAN | Use of α1C specific compounds to treat benign prostatic hyperlasia |
Nov, 2012
(11 years ago) | |
| US5780485 | ALLERGAN | Use of α1c specific compounds to treat benign prostatic hyperplasia |
Nov, 2012
(11 years ago) | |
| US6015819 | ALLERGAN | Use of alpha-1C specific compounds to treat benign prostatic hyperplasia |
Nov, 2012
(11 years ago) | |
Rapaflo is owned by Allergan.
Rapaflo contains Silodosin.
Rapaflo has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Rapaflo are:
- US5403847
- US5780485
- US6015819
- US5387603
Rapaflo was authorised for market use on 08 October, 2008.
Rapaflo is available in capsule;oral dosage forms.
Rapaflo can be used as use in the treatment of the signs and symptoms of benign prostatic hyperplasia (bph).
Drug patent challenges can be filed against Rapaflo from 08 October, 2012.
The generics of Rapaflo are possible to be released after 01 December, 2018.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 08, 2013 |
Drugs and Companies using SILODOSIN ingredient
NCE-1 date: 08 October, 2012
Market Authorisation Date: 08 October, 2008
Treatment: Use in the treatment of the signs and symptoms of benign prostatic hyperplasia (bph)
Dosage: CAPSULE;ORAL
RAPAFLO family patents
